Translating Promise into Progress at ASCO 2026

At scientific meetings, “translation” can sound like a technical term — shorthand for moving discoveries from the lab into the clinic. But in oncology, it means something broader.

Translation is the process of turning scientific insight into real-world relevance: understanding disease biology more deeply, identifying the right targets, testing new approaches, and building evidence that can help shape treatment decisions in the future.

At BeOne, that process is ultimately about better understanding, better decisions, and better possibilities for patients. It also reflects how we work: connecting discovery, development, and evidence generation across disease areas so promising insights can move forward with focus and urgency.

That is part of what makes ASCO 2026’s theme feel so timely. Cancer research is producing more insight than ever before. The real question is how these insights influence clinical decision-making, what researchers pursue next, and what becomes possible for patients.

Across 24 abstracts in hematology and solid tumors, the research BeOne is presenting reflects more than scientific momentum. It reflects our deliberate approach to oncology: building leadership in focused disease areas, investing in diverse therapeutic modalities, and generating evidence that spans both foundational therapies and next-generation pipeline programs.

In hematology, that includes continued work in blood cancers where standards of care have evolved quickly, and important questions remain around sequencing, depth of response, and what durable progress can look like over time. It also includes long-term follow-up that can deepen confidence in treatment pathways already shaping care today, while building on foundational approaches that have helped reshape expectations for treatment over time.

In solid tumors, we are presenting research across breast, gynecologic and gastrointestinal cancers — concentrating on disease areas with significant unmet need. The work spans early clinical development as well as analyses that help deepen understanding of how therapies may perform across patient groups and treatment settings.

Taken together, this research reflects how BeOne has been built over time: starting with foundational progress in B-cell malignancies and expanding a broader portfolio designed to address unmet need across both solid tumors and blood cancers.

One of the clearest messages in our ASCO research is that progress in oncology is becoming more connected — across modalities, evidence, and the questions researchers are trying to answer.

This year’s presentations are studies involving bispecific antibodies, antibody-drug conjugates, selective inhibitors, and immunotherapy-based combinations. Each reflects a different way of trying to solve hard problems in cancer care: how to target cancer more precisely, how to improve treatment strategies, and how to advance quickly in areas where there is an urgent unmet need.

Just as important, the work spans evidence types to provide a fuller picture of a potential or current therapy. Some of the research focuses on early clinical development. Some looks at longer-term outcomes. Some explores biomarkers that may sharpen understanding of response. Some examines patient-reported outcomes and other measures that help connect treatment effects to lived experience.

This is what translation looks like in practice. It is not only about advancing new science. It is about building the evidence that helps make that science meaningful — in context, in care, and over time.

For those living with cancer, progress is not measured by the number of abstracts presented at a meeting. It is measured by whether research is leading to better answers, and ultimately better treatment outcomes.

Sometimes that progress appears in a new approach being tested in a hard-to-treat cancer. Sometimes it comes from longer-term data that deepens confidence in a treatment pathway already in use. Sometimes it comes from learning more clearly which patients may benefit most from a given approach.

At BeOne, our commitment to a patient-first mindset helps shape how we think about research, and is reflected in a portfolio spanning hematology and solid tumors, foundational therapies and emerging investigational assets, current care and future possibilities. We believe better outcomes start with better questions, deeper evidence, and the discipline to keep translating science into more clarity, more options, and more reason for hope.